Építés alatt – nem éles oldal
Belépés
Résztvevőt keres1. fázis

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

A legfontosabb adatok

Ki végzi
Chugai Pharmaceutical
Hol
Warsaw (Lengyelország)A helyszín megnézéseMég 19 másik országban, 75 helyszínen
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
144 fő, tervezett
Kezdés
2024. aug. 19.
Várható befejezés
2027. jún. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • RAY121
A regiszteradat frissítve
2026. július 22.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with one of these immune diseases: antiphospholipid syndrome (APS), bullous pemphigoid, Behçet's syndrome, dermatomyositis, immune-mediated necrotizing myopathy or immune thrombocytopenia (ITP). Everyone gets the study drug RAY121.

Életkor
18 to 85 years
Nem
All sexes
A betegség stádiuma
Each disease group has its own rules. Bullous pemphigoid: BPDAI score >= 20 and itch score >= 4. Behçet's: repeated mouth ulcers needing whole-body treatment. Dermatomyositis: moderate to severe, CDASI activity score > 14, MMT-8 score < 142. Necrotizing myopathy: CK > 1,000 U/L, MMT-8 score < 142. ITP: persistent or chronic, platelet count <= 30 × 10^9/L twice in a row. Karnofsky score ≥ 60 %.
Korábbi kezelés
Behçet's: at least 1 earlier non-biologic treatment. Dermatomyositis and necrotizing myopathy: corticosteroids and/or immune-suppressants did not work well enough or were not tolerated. ITP: a thrombopoietin receptor agonist and at least one other ITP treatment did not keep platelets up, but an earlier treatment once raised platelets by more than 20 × 10^9/L. People who ever had an anti-C1s antibody, or other complement inhibitors within 3 months, cannot join.
Biomarker vagy leletérték
APS: persistently positive LA, aCL IgG or aβ2GPI IgG test. Bullous pemphigoid: positive direct immunofluorescence plus positive indirect immunofluorescence or BP180 antibody test. Necrotizing myopathy: anti-HMGCR or anti-SRP myopathy.

A részvétel fő kizáró okai

  • Pregnant, breastfeeding or planning a pregnancy
  • Active infection needing antiviral, antibiotic or antifungal medicine; hepatitis B, hepatitis C, HIV or current tuberculosis
  • Cancer within the last 5 years
  • Other autoimmune diseases besides the studied one (Sjögren's syndrome allowed in dermatomyositis and myopathy)
  • Severe allergic reaction to a biologic drug, or planned surgery during the study

A regiszter feltételei, szó szerint

Mind a 35 feltétel megnézéseKevesebb

Ki nem vehet részt

  • Planned surgery during the study
  • Illicit drug or alcohol abuse
  • Positive for human immunodeficiency virus antibody
  • Treatment with investigational therapy within 28 days or 5 half-lives
  • Previous and current treatment with anti-C1s antibody at any time
  • Other complement inhibitors within 3 months
  • Patients who receive any treatments which fall into the Prohibited Therapy Criteria
  • APS cohort:; 1) APS associated with other systemic autoimmune disease; 2) Acute thrombosis (arterial or venous acute thrombosis diagnosis) within 30 days before screening; 3) Patients with thrombotic APS without any anticoagulation treatment; 4) Treatment with prohibited medications
  • BP cohort:; ・ 1) Initiation of treatment with or increase in the dose of systemic or topical corticosteroid within 2 weeks; 2) Current treatment with a drug that may cause or exacerbate BP unless the dose has been stable; 3) Initiation of treatment with topical calcineurin inhibitor, or topical phosphodiesterase (PDE) 4 inhibitor within 7 days; 4) Treatment with prohibited medications
  • BS cohort:; ・ 1) BS-related active major organ involvement-ocular lesions requiring immunosuppressive therapy, pulmonary (e.g., pulmonary artery aneurysm), vascular (e.g., thrombophlebitis), gastrointestinal (e.g., ulcers along the gastrointestinal tract), and central nervous systems (e.g., meningoencephalitis) manifestations; 2) History of venous or arterial thrombosis within 1 year; 3) Treatment with prohibited medications
  • DM cohort:; ・ 1) PhGA-VAS improvement >= 3, or clinically relevant improvement between screening and baseline; 2) Overlap myositis (except for overlap with Sjögren's syndrome), connective tissue disease associated DM, inclusion body myositis, polymyositis, IMNM, juvenile DM or drug-induced myopathy; 3) Cancer-associated myositis; 4) Significant muscle damage; 5) Past history of severe Interstitial lung disease flare, severe non-infectious lung inflammation which required active intervention, or multiple episodes of lung disease; 6) Severe respiratory muscle weakness; 7) Severe bulbar palsy; 8) Treatment with prohibited medications
  • IMNM cohort:; ・ 1) PhGA-VAS improvement >= 3, or clinically relevant improvement between screening and baseline; ・ 2) Overlap myositis (except for overlap with Sjögren's syndrome), connective tissue disease associated DM, inclusion body myositis, polymyositis, juvenile DM or druginduced myopathy; ・ 3) Cancer-associated myositis; ・ 4) Significant muscle damage; ・ 5) Past history of severe Interstitial lung disease (ILD) flare, severe non-infectious lung inflammation which required active intervention, or multiple episodes of lung disease; ・ 6) Severe respiratory muscle weakness; ・ 7) Severe bulbar palsy; ・ 8) Treatment with prohibited medications
  • History of anaphylaxis or hypersensitivity to a biologic agent
  • Active infection requiring systemic antiviral, antibiotics or antifungal
  • Clinical diagnosis of autoimmune diseases other than the target disease (except for Sjögren's syndrome in DM and IMNM)
  • Positive for hepatitis B surface antigen
  • Positive for hepatitis C virus antibody
  • Evidence of current infection with tuberculosis
  • History of cancer within 5 years
  • Any serious medical condition or abnormality in clinical laboratory tests that precludes the patient's safe participation in and completion of the study
  • Patients with an elevated alanine aminotransferase or aspartate aminotransferase > 1.5 × ULN in combination with an elevated total bilirubin > 1.5 × ULN
  • ITP cohort:; ・ 1) Secondary ITP; ・ 2) Clinical diagnosis or history of Myelodysplastic Syndrome or autoimmune hemolytic anemia; ・ 3) History of venous or arterial thrombosis within 12 months; ・ 4) Patients who experienced major bleeding within 4 weeks; 5) Treatment with prohibited medications; 6) Any laboratory test results meet either of the following criteria at screening:; Hemoglobin <10 g/dL; Thyroid-stimulating hormone >= 10 μIU/mL
  • Pregnant or breastfeeding, or intending to become pregnant
  • Clinically significant ECG abnormalities

Egyéb feltételek

  • Signed informed consent form
  • Age ≥ 18 and ≤ 85 at the time of signing informed consent form with Karnofsky score ≥ 60 % at screening
  • Ability to comply with the study protocol
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm
  • APS cohort: Established primary APS defined by the following criteria (at least one of the laboratory criteria and one of the clinical criteria must be met):; Laboratory criteria (aPL profile); Persistently positive LA test; Persistently positive aCL IgG isotype; Persistently positive aβ2GPI IgG isotype; Clinical criteria; Livedoid vasculopathy and presence of skin ulcer; Acute/chronic aPL nephropathy
  • BP cohort:
  • Predominant cutaneous lesions 2) Diagnosis with BP with following assessments positive:
  • Positive direct immunofluorescence, and either
  • Positive indirect immunofluorescence, or
  • Positive serology on ELISA for BP180 autoantibody 3) BPDAI score >= 20 4) Weekly average of daily Peak Pruritus NRS >=4 5) Accept to take photograph of bullous lesions; BS cohort:; Diagnosed with BS; Oral ulcers that occurred at least 3 times in the previous 12 month period; Have at least 2 oral ulcers over the 4 weeks prior to screening; Have at least 2 oral ulcers at Week 0; Have prior treatment with at least 1 non-biologic BS therapy; Patients who need systemic therapy as whose oral or mucocutaneous ulcers cannot be adequately controlled by topical therapy; DM cohort:; Diagnosed with definite or probable inflammatory myopathies and categorized as DM; Patients with inadequate response to corticosteroids and/or immune-suppressants or intolerance to DM therapies; MMT-8 score < 142, with at least one abnormality in the following Core Set Measures:; PtGA-VAS >= 2 cm; PhGA-VAS >= 2 cm; Global extra-muscular activity >= 2 cm; At least one muscle enzyme > 1.5 times ULN; HAQ >= 0.25; Moderate to severe DM defined as CDASI activity score > 14; IMNM cohort:; Clinically Diagnosed with IMNM as anti-HMGCR myopathy or anti-SRP myopathy; CK > 1,000 U/L; Patients who have an inadequate response to corticosteroids and/or immunesuppressants or intolerance to IMNM therapies; MMT-8 score < 142; ITP cohort:; Confirmed diagnosis of persistent/chronic ITP based on the following criteria:; ITP defined per the current guidelines; Platelet count <= 30 × 10\^9/L on 2 consecutive occasions; Lack of an sustained adequate platelet count response to a thrombopoietin receptor agonist and at least one other ITP treatment or a second TPO-RA; A history of response with an platelet counts increase more than 20 × 10\^9/L from baseline by at least one prior line of therapy

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 85 év között vagy?

Helyszínek itt: Lengyelország

Még 19 másik országban, 75 helyszínen

  • Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory ReicherWarsaw, LengyelországNo longer taking part

A vizsgálatról

Mit akar kideríteni a vizsgálat

This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).

A vizsgálat csoportja

  • RAY121A vizsgált kezelés

    All enrolled patients will receive RAY121 multiple dose

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Phase 1b Open-label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT06371417: ki vehet részt
A regiszteradat frissítve
2026. július 22.